Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen

Table 1

Demographic and clinical characteristics of the included eyes.

Characteristics	Aflibercept	Ranibizumab	Total	P- value
No of Patients (%)	39 (61,90)	24 (38,10)	63 (100)
No of eyes (%)	42 (58,33)	30 (41,67)	72 (100)
Demographic Characteristics
Age, mean ± SD	78,02 ± 7,17	82,15 ± 6,12	79,81 ± 7,01	0,016
Gender, n (%)				0,117
Female	20 (47,6)	20 (66,7)	40 (55,6)
Male	22 (52,4)	10 (33,3)	32 (44,4)
Clinical Characteristics
Baseline BCVA, mean ± SD	53,33 ± 17,02	52,16 ± 14,4	52,82 ± 17,12	0,661
Baseline CRT, mean ± SD	408,14 ± 117,84	379,71 ± 110,51	396,77 ± 115,01	0,786
No Injections 12m, mean ± SD	5,86 ± 0,84	5,47 ± 1,14	5,68 ± 0,99	0,055
No Injections 18m, mean ± SD	7,57 ± 1,48	6,59 ± 1,45	7,15 ± 1,61	0,064
Protocol interruption, n (%)	0	3 (10)	3 (4,17)	0,041

No: number, SD: standard deviation, BCVA: best corrected visual acuity, CRT: central retinal thickness, m: month